Last Updated on October 17, 2024 by The Health Master
Drug firm Cipla on Thursday said it has received approval from the US health regulator to market Difluprednate Ophthalmic Emulsion, used in the treatment of inflammation and pain associated with ocular surgery, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Novartis Pharmaceutical Corporation’s Durezol, Cipla said in a statement.
The product is also used for the treatment of endogenous anterior uveitis.
According to IQVIA (IMS Health), Durezol had US sales of around USD 106 million for the 12-month period ending June 2021.
The product will be available for shipping soon, the Mumbai-based drug major said.
Shares of Cipla were trading 0.29 per cent up at Rs 912.90 apiece on the BSE.
Alembic gets USFDA nod for Clomipramine HCL Capsules
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Zydus Cadila gets USFDA nod for Ibrutinib tablets
Lupin gets USFDA nod for generic Antifungal drug
Latest Notifications regarding Pharmaceuticals
Why to include Peptides in your Skincare Products ?
DCGI classifies 135 Ophthalmology, 51 respiratory Medical Devices
Govt approves Bharat Biotech’s plant for Covaxin production
PLI scheme for 100 Chemicals, APIs and Intermediates to be formulated…
Lok Sabha passes amendment bills on Homoeopathy, National Commission for Indian…
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
